Wedbush analyst Andreas Argyrides reiterated a Buy rating on Gossamer Bio (GOSS - Research Report) today and set a price target of $19.00. The company's shares opened today at $10.40.Argyrides covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, BioMarin Pharmaceutical, and Albireo Pharma. According to TipRanks, Argyrides has an average return of -11.0% and a 42.55% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gossamer Bio with a $19.14 average price target, representing an 84.04% upside.
https://www.tipranks.com/news/blurbs/wedbush-sticks-to-their-buy-rating-for-gossamer-bio-goss?utm_source=advfn.com&utm_medium=referral
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Nov 2023 to Dec 2023 Click Here for more Gossamer Bio Charts.
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Dec 2022 to Dec 2023 Click Here for more Gossamer Bio Charts.